Therefore, we evaluated the toxicity and efficacy of escalating doses of oral TMZ followed by subcutaneous injections of low-dose IL2, GM-CSF and IFNα in a phase I/II trial in patients with metastatic melanoma. The gene discussed is IL2; the disease is metastatic melanoma.